WiL Academy Singapore CAR T Educational Internship

The WiL Academy is a pioneering educational initiative aimed at promoting health equity in the rapidly evolving field of CAR T therapy. This program offers an opportunity for female clinicians from around the world to advance their knowledge in CAR T therapy, a cutting-edge treatment for lymphoma. Singapore is a hub for access to CAR T cells in Southeast Asia. 

The WiL Academy program in Singapore can serve as a central training site for female clinicians from Southeast Asia, where access to advanced therapies like CAR T may be limited or emerging. The first prototype of the WiL Academy CAR T Educational Internship is developed in collaboration with The National University Cancer Institute Singapore (NCIS), one of the leading centres in South East Asia for CAR T therapy with expertise in patient selection, treatment administration, and management of post-treatment side effects. 

The internship will consist of two female clinicians attending at the same time. The program is structured in three phases:

Phase 1: Review the main indications for CAR-T cells in both adults and pediatrics.

Phase 2: (running concurrently with Phase 3): Follow the CAR T cell journey, including T-cell collection, modification, lymphodepleting chemotherapy, CAR T infusion, early recovery, and long term recovery.

Phase 3: Follow the patient’s journey through pre-treatment evaluation, tumour board discussion, visits to the cellular therapy unit, hematology unit, and discussions with CAR-T clinical coordinators.

In addition, there will also be lectures and discussions to provide practical information to guide clinicians in setting up their CAR T program. 

Through this collaboration with the National University Cancer Institute Singapore (NCIS), the Singapore General Hospital, the Asia-Pacific Blood and Marrow Transplantation Group (APBMT) and the Advanced Cell Therapy and Research Institute (ACTRIS), the WiL Academy Singapore aims to leverage regional networks in Southeast Asia to support female clinicians in the field.